Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Liabilities and Shareholders Equity (2016 - 2025)

Avanos Medical's Liabilities and Shareholders Equity history spans 11 years, with the latest figure at $1.7 billion for Q3 2024.

  • For Q3 2024, Liabilities and Shareholders Equity fell 3.98% year-over-year to $1.7 billion; the TTM value through Dec 2024 reached $5.0 billion, down 27.04%, while the annual FY2023 figure was $1.7 billion, 5.29% down from the prior year.
  • Liabilities and Shareholders Equity for Q3 2024 was $1.7 billion at Avanos Medical, roughly flat from $1.7 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $1.8 billion in Q3 2020 and bottomed at $1.6 billion in Q3 2021.
  • The 5-year median for Liabilities and Shareholders Equity is $1.7 billion (2023), against an average of $1.7 billion.
  • The largest annual shift saw Liabilities and Shareholders Equity dropped 11.18% in 2021 before it rose 11.43% in 2022.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $1.7 billion in 2020, then fell by 4.14% to $1.6 billion in 2021, then rose by 11.43% to $1.8 billion in 2022, then decreased by 5.29% to $1.7 billion in 2023, then fell by 2.14% to $1.7 billion in 2024.
  • Per Business Quant, the three most recent readings for AVNS's Liabilities and Shareholders Equity are $1.7 billion (Q3 2024), $1.7 billion (Q2 2024), and $1.7 billion (Q1 2024).